# Fucoxanthin inhibits the proliferation of MOLM13 cells by targeting AKT to disrupt glucose metabolism

**Authors:** Tingting Niu, Ying Chen, Mengmeng Sun, Cong Shi, Duobing Zou, Wei Wu, Yuzhan Chen, Juanjuan Chen, Haimin Chen, Guifang Ouyang, Qitian Mu

PMC · DOI: 10.3389/fphar.2025.1601281 · 2025-07-15

## TL;DR

Fucoxanthin, a natural compound, inhibits the growth of a type of leukemia cell by targeting a protein called AKT and disrupting glucose metabolism.

## Contribution

The study reveals that fucoxanthin directly targets AKT to inhibit glucose metabolism in FLT3-ITD AML cells.

## Key findings

- Fucoxanthin reduced MOLM13 cell viability by 63.6% and induced G0/G1 arrest and apoptosis.
- It inhibited glucose uptake, GLUT1 translocation, and ATP production in these cells.
- Molecular dynamics showed key interactions between fucoxanthin and AKT residues Phe-236 and Lys-179.

## Abstract

Fucoxanthin is a natural carotenoid that has remarkable anti-tumor effects and an excellent safety profile. Here, we combined molecular docking, dynamics simulations, and functional assays (CCK-8, flow cytometry, glucose/ATP detection) to decipher the mechanism of Fucoxanthin on FLT3-ITD AML cells. Fucoxanthin (25 μM) reduced MOLM13 (FLT3-ITD) cell viability by 63.6% (P < 0.01), inducing G0/G1 arrest via CDK4 downregulation and apoptosis through Bcl2 suppression. Fucoxanthin also inhibited the glucose uptake, GLUT1 membrane translocation, and ATP production. Mechanistically, fucoxanthin directly bound to AKT and inhibited its kinase activity by 57.9%, while AKT overexpression rescued the glucose/ATP suppression (P < 0.05). Molecular dynamics revealed critical interactions between fucoxanthin and Phe-236/Lys-179. These results suggest that fucoxanthin may selectively target AKT-dependent glucose metabolism in MOLM13 cells, warranting further investigation into its role in addressing metabolic alterations in FLT3-ITD AML.

## Linked entities

- **Genes:** CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513]
- **Proteins:** AKT1 (AKT serine/threonine kinase 1)
- **Chemicals:** Fucoxanthin (PubChem CID 5281239)
- **Diseases:** AML (MONDO:0018874)

## Full-text entities

- **Genes:** CDK6 (cyclin dependent kinase 6) [NCBI Gene 1021] {aka MCPH12, PLSTIRE}, H3P16 (H3 histone pseudogene 16) [NCBI Gene 644914] {aka H3.6, H3F3AP6, p21}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, BCL2L1 (BCL2 like 1) [NCBI Gene 598] {aka BCL-XL/S, BCL2L, BCLX, Bcl-X, PPP1R52}, CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, HK1 (hexokinase 1) [NCBI Gene 3098] {aka CNSHA5, HK, HK1-ta, HK1-tb, HK1-tc, HKD}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, CCNB1 (cyclin B1) [NCBI Gene 891] {aka CCNB}, TBC1D4 (TBC1 domain family member 4) [NCBI Gene 9882] {aka AS160, NIDDM5}, STAT5A (signal transducer and activator of transcription 5A) [NCBI Gene 6776] {aka MGF, STAT5}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, FLT3 (fms related receptor tyrosine kinase 3) [NCBI Gene 2322] {aka CD135, FLK-2, FLK2, STK1}, PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GADD45A (growth arrest and DNA damage inducible alpha) [NCBI Gene 1647] {aka DDIT1, GADD45}, BAD (BCL2 associated agonist of cell death) [NCBI Gene 572] {aka BBC2, BCL2L8}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, PFKM (phosphofructokinase, muscle) [NCBI Gene 5213] {aka ATP-PFK, GSD7, PFK-1, PFK-A, PFK1, PFKA}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}
- **Diseases:** hepatocellular carcinoma (MESH:D006528), melanoma (MESH:D008545), adult T-cell leukemia (MESH:D015459), hematological tumors (MESH:D019337), PC-3 prostate cancer (MESH:D011471), Cancer (MESH:D009369), bladder cancer (MESH:D001749), cytopenias (MESH:D006402), Pharyngeal Squamous Cell Carcinoma (MESH:D002294), cardiotoxicity (MESH:D066126), obesity (MESH:D009765), thyroid cancer (MESH:D013964), HL-60 leukemia (MESH:C538324), glioblastoma (MESH:D005909), leukemia (MESH:D007938), breast cancer (MESH:D001943), AML (MESH:D015470), colon cancer (MESH:D015179), gastric adenocarcinoma (MESH:D013274), febrile neutropenia (MESH:D064147), cytotoxicity (MESH:D064420)
- **Chemicals:** SDS (MESH:D012967), Carotenoids (MESH:D002338), lycopene (MESH:D000077276), FF-10101 (MESH:C000631067), cisplatin (MESH:D002945), midostaurin (MESH:C059539), hydrogen (MESH:D006859), Phe (MESH:D010649), propidium iodide (MESH:D011419), Ficoll (MESH:D005362), water (MESH:D014867), polyacrylamide (MESH:C016679), CO2 (MESH:D002245), imatinib (MESH:D000068877), Fucoxanthin (MESH:C025164), 7-AAD (MESH:C025942), doxorubicin (MESH:D004317), astaxanthin (MESH:C005948), ethanol (MESH:D000431), CCK-8 (MESH:D012844), PVDF (MESH:C024865), trypan blue (MESH:D014343), gilteritinib (MESH:C000609080), allene (MESH:C025947), Glucose (MESH:D005947), NAD+ (MESH:D009243), ATP (MESH:D000255), 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (MESH:C098340), salt (MESH:D012492), 3.1 Fucoxanthin (-), citric acid (MESH:D019343)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], HC [taxon 11103]
- **Mutations:** Jak2-V617F
- **Cell lines:** OCI-AML2 — Homo sapiens (Human), Adult acute myeloid leukemia, Cancer cell line (CVCL_1619), U251 glioma — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_0021), HL-60 — Homo sapiens (Human), Adult acute myeloid leukemia with maturation, Cancer cell line (CVCL_0002), NB4 — Homo sapiens (Human), Acute promyelocytic leukemia with PML-RARA, Cancer cell line (CVCL_0005), U937 — Homo sapiens (Human), Adult acute monocytic leukemia, Cancer cell line (CVCL_0007), KG-1alpha — Homo sapiens (Human), Acute myeloid leukemia without maturation, Cancer cell line (CVCL_1824), MOLM13 — Homo sapiens (Human), Adult acute monocytic leukemia, Cancer cell line (CVCL_2119), HEK-293T — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12303925/full.md

---
Source: https://tomesphere.com/paper/PMC12303925